Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease

This secondary analysis of a randomized clinical trial investigates the association of donanemab treatment with plasma biomarkers associated with Alzheimer disease.

[1]  O. Hansson,et al.  Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials , 2022, The Lancet Neurology.

[2]  F. Barkhof,et al.  Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease , 2022, The Journal of Prevention of Alzheimer's Disease.

[3]  O. Hansson,et al.  Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels , 2022, Acta Neuropathologica Communications.

[4]  D. Rentz,et al.  Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimates , 2022, Alzheimer's & dementia.

[5]  O. Hansson,et al.  Blood‐based biomarkers for Alzheimer's disease , 2021, EMBO molecular medicine.

[6]  W. Flier,et al.  Blood-based biomarkers for Alzheimer's disease: towards clinical implementation , 2021, The Lancet Neurology.

[7]  K. Blennow,et al.  Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum , 2021, JAMA neurology.

[8]  C. Jack,et al.  Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[9]  A. Fleisher,et al.  Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging , 2021, The Journal of Prevention of Alzheimer's Disease.

[10]  K. Blennow,et al.  Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease , 2021, JAMA neurology.

[11]  K. Blennow,et al.  Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease , 2021, Brain : a journal of neurology.

[12]  K. Blennow,et al.  Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[13]  D. Holtzman,et al.  A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis , 2021, Molecular Neurodegeneration.

[14]  M. Mintun,et al.  Donanemab in Early Alzheimer's Disease. , 2021, The New England journal of medicine.

[15]  Anonymous,et al.  2021 Alzheimer's disease facts and figures , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[16]  K. Blennow,et al.  Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease , 2021, Translational Psychiatry.

[17]  S. Shcherbinin,et al.  Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease , 2021, Alzheimer's & dementia.

[18]  O. Hansson,et al.  Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease , 2020, JAMA neurology.

[19]  D. Walsh,et al.  Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease , 2020, Brain : a journal of neurology.

[20]  P. Scheltens,et al.  Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease , 2020, Scientific Reports.

[21]  K. Blennow,et al.  Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. , 2020, JAMA.

[22]  Tianming Liu,et al.  Neurochemical regulation of the expression and function of glial fibrillary acidic protein in astrocytes , 2020, Glia.

[23]  Philip S. Insel,et al.  Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease , 2020, Science Advances.

[24]  A. Lloret,et al.  When Does Alzheimer′s Disease Really Start? The Role of Biomarkers , 2019, International journal of molecular sciences.

[25]  K. Blennow,et al.  Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. , 2019, JAMA neurology.

[26]  K. Blennow,et al.  Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status , 2019, JAMA neurology.

[27]  Dag Aarsland,et al.  Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration , 2019, Acta neuropathologica communications.

[28]  S. Salloway,et al.  Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE) , 2018, Alzheimer's Research & Therapy.

[29]  Ludwig Kappos,et al.  Neurofilaments as biomarkers in neurological disorders , 2018, Nature Reviews Neurology.

[30]  Dean F. Wong,et al.  Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale , 2018, Alzheimer's & Dementia.

[31]  M. Mintun,et al.  Test–Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18 , 2017, The Journal of Nuclear Medicine.

[32]  M. Andjelkovic,et al.  A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease , 2017, Alzheimer's Research & Therapy.

[33]  Yue-Ming Li,et al.  The role of astrocytes in amyloid production and Alzheimer's disease , 2017, Open Biology.

[34]  Hang Su,et al.  Plasma neurofilament light chain levels in Alzheimer’s disease , 2017, Neuroscience Letters.

[35]  Henrik Zetterberg,et al.  Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease , 2017, JAMA neurology.

[36]  M. Mintun,et al.  Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition , 2017, Brain : a journal of neurology.

[37]  E. Siemers,et al.  A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS). , 2015, The journal of prevention of Alzheimer's disease.

[38]  Mark A. Mintun,et al.  A Semiautomated Method for Quantification of F 18 Florbetapir PET Images , 2015, The Journal of Nuclear Medicine.

[39]  M. Sofroniew,et al.  Astrocytes: biology and pathology , 2009, Acta Neuropathologica.

[40]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[41]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2000, The Journal of the American College of Dentists.

[42]  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2013, JAMA.